F ractional flow reserve (FFR) has been validated as a reliable surrogate for inducible ischemia, 1 supporting its use during invasive procedures for functional assessment of coronary lesions. Landmark randomized trials have
FFR Impact on Decision Making and 1-Year Outcome
revascularization is associated with a better clinical outcome up to 2 years, when compared with standard angiography. 3 Results from the FAME 2 (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation 2) study suggested that deferring the revascularization of epicardial stenosis with an FFR≤0.80 was associated with an 11.4% absolute increase in the risk of major cardiovascular events at 24 months (8.1% in revascularized patients versus 19 .5% in medically treated), an hazard that was mainly driven by urgent revascularization. 4 In spite of the overwhelming evidence of its potential clinical and economic benefits 5 and strong guideline recommendation, 6 the adoption of FFR in the real-world is perceived to vary significantly. Reasons for this disparity are several, but most operators still do rely the most on angiographic eyeballing to decide on the functional significance of coronary lesions and the need for revascularization. 7 The Portuguese Study on the Evaluation of FFR-Guided Treatment of Coronary Disease (POST-IT) was a prospective registry designed to describe the patterns of the use of FFR in an unselected real-world population, to assess its impact on clinical decision making-concerning both lesion and patient management-and the 1-year outcome of such a strategy.
Methods

Study Design and Patient Population
The POST-IT registry was an investigator-initiated observational study, designed to prospectively include all patients referred for coronary angiography in which at least 1 lesion was evaluated by FFR. All centers capable of performing FFR were invited to participate and there were no predefined exclusion criteria, other than the patient's unwillingness to provide written informed consent and life expectancy <1 year because of known noncardiovascular comorbidity. The decision to perform FFR was left to the operator in each case.
The study primary purpose was to evaluate the clinical outcome of a management strategy based on FFR evaluation of patients referred for angiography with suspected or confirmed obstructive coronary artery disease on routine daily practice. The impact of FFR on decision making (revascularization versus medical therapy versus further noninvasive stress test), both per-lesion and per-patient, was also assessed.
Data Collection and Monitoring
Patient baseline and procedural characteristics were prospectively collected at the time of inclusion and recorded in a dedicated electronic case report form. To ensure the quality and reliability of the data, external monitoring was undertaken.
FFR Cutoff and Management Strategy
As part of the inclusion algorithm, treating physicians were asked to establish a management plan for each lesion (revascularization, medical therapy or noninvasive stress test) based on all available information before and after FFR determination. Agreement between the final and initial strategies was recorded for each evaluated lesion and per-patient. There was no specific recommendation whether to use any of the cutoffs previously validated in randomized trials (0.75 or 0.80). Clinical decisions were entirely left at the operators' discretion. Please refer to the Data Supplement file for a detailed description.
Clinical Follow-Up and End Point Definition
Patients were followed for 12 months after the index procedure for the occurrence of the composite primary end point (MACE) of death from cardiovascular causes, myocardial infarction (MI) or new unplanned revascularization (please refer to the Data Supplement file for detailed definitions of all study end points). An independent committee reviewed each reported event for consistency before final adjudication. For the purpose of the outcome analysis, the population was divided into 3 groups according to the management of lesions and patients in a way that they would resemble relevant populations in randomized trials as much as possible: group 1 consisted of patients in whom all lesions evaluated were deferred based on an FFR>0.80 and no other lesions were revascularized; group 2 consisted of patients who underwent percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) of at least 1 lesion either during the index procedure or subsequently; and finally, patients in group 3 were those in whom at least 1 lesion with an FFR≤0.80 was left untreated. A similar approach was chosen for the per-lesion analysis: group 1, deferred lesions with FFR>0.80; group 2, lesions revascularized, regardless of FFR value; and group 3, lesions with FFR≤0.80 who were not treated.
Statistical Analysis
Continuous variables with normal distribution were expressed as means and SD. Continuous variables with a non-normal distribution were expressed as median and interquartile range. Normality was tested with the Kolmogorov-Smirnov test and Q-Q Plot visual assessment. Discrete variables were expressed as percentages. Agreement between initial and post-FFR treatment strategy was assessed by the Cohen κ test. Whenever necessary, comparison of baseline characteristics or outcomes was performed using the χ 2 test, with Yates correction when appropriate, for categorical variables, the Student t test, the Satterthwaite test or 1-way ANOVA for continuous variables with normal distribution and the Kruskal-Wallis test for continuous variables with a non-normal distribution. Unadjusted event-free survival was evaluated by Kaplan-Meier estimates and statistical significance assessed by the log-rank test. Adjusted risk estimates were obtained using Cox proportional hazard models, including variables found to differ significantly between groups on univariate analysis or deemed to be clinically relevant. A detailed description of these variables is presented in the Methods section of the Data Supplement. For all comparisons, a P value of <0.05 was considered statistically significant. When appropriate, 95% confidence intervals (CIs) were calculated. Statistical analysis was performed with IBM SPSS Statistics version 19.0 (SPSS Inc, Chicago, IL).
Ethics and Regulation
The study was undertaken according to best clinical practices and all patients provided written informed consent. The protocol complies with the Declaration of Helsinki and was approved by institutional review boards at each participating site. A registration was made on the
WHAT IS KNOWN
• Fractional flow reserve-guided revascularization has been shown to improve clinical outcomes and reduce costs in patients involved in clinical trials.
WHAT THE STUDY ADDS
• Assessment of lesion severity using fractional flow reserve has the potential to safely change treatment strategy in a high proportion of cases. 
Results
Population Baseline Characteristics
From March 2012 to November 2013, 918 patients were enrolled in 19 hospitals. Inclusion rate per participating center is summarized in Table I in the Data Supplement. The flowchart of patient inclusion is shown in Figure 1 , and population baseline characteristics are depicted in Table and in Table II in the Data Supplement. Despite the main indication for coronary angiography was suspected or known stable coronary artery disease, a significant proportion of patients (35.4%) were enrolled in the setting of an acute coronary syndrome (ACS), either recent or ongoing. Although some differences existed between the 3 study groups, there was no clear clustering of adverse characteristics known to decisively influence hard clinical outcomes.
Lesion Characteristics and FFR Procedure
A total of 1293 lesions were evaluated (1.4 per patient). The main characteristics of study lesions, according to the revascularization strategy, are detailed in the Table III in the Data Supplement. The overall success rate of the FFR procedure was 99.4% (1285/1293 lesions). Operator-reported reasons for unsuccessful FFR evaluation were the inability to cross the lesion with the pressure guidewire (n=4), acute target lesion occlusion after wiring (n=2), excessive bradycardia (n=1), and equipment malfunction (n=1). Average FFR was 0.81±0.10 and decreased significantly with increasing stenosis severity ( Figure I in the Data Supplement). Overall, target lesions were treated according to FFR information in 93% of the cases (1195/1285; Figure 2 ) and 154 patients (16.8%) underwent PCI of at least 1 lesion not evaluated by FFR during the index procedure.
Management Strategy
Strategy Change: Per-Patient Analysis
In as many as 406 patients (44.2%), final treatment decision was not consistent with the baseline plan (Cohen κ, 0.33; Figure   3A ). The proportion of patients ultimately undergoing revascularization after FFR was known was higher than planned at baseline: it increased from 34.8% to 44.0% for PCI and from 4.1% to 8.3% for CABG ( Figure II in the Data Supplement). Even when patients initially considered for additional noninvasive stress testing were excluded, still the absolute number of patients finally undergoing PCI and CABG increased (from 319 to 321 and from 38 to 49, respectively).
Strategy Change: Per-Lesion Analysis
After FFR evaluation, management strategy changed in 45.2% of the lesions (584/1293). Globally ( Figure 3B ), the number of revascularized lesions (by PCI or CABG) increased from the initially planned 374 (28.9%) to a final 497 (38.4%).
One-Year Clinical Outcome
Per-Patient Analysis
Complete 12-month follow-up was available for 912 of 918 patients (99.3%) and vital status was known for 916 (99.8%; Figure 1 ). Total MACE was 6.9% at 12 months in the entire cohort and was the lowest in group 1 patients (5.3%). The stepwise increase in total MACE across groups was statistically significant in an unadjusted analysis of the crude incidence (P=0.043, Figure 4A ; Table IV in the Data Supplement), but not after correction for relevant differences in baseline characteristics ( Figure 5A ). The pattern was similar when only ischemia-driven events were considered. Freedom from the primary end point at 12 months was 94.6% in patients in whom management decisions changed based on FFR versus 91.9% in those with concordant decisions between baseline and post-FFR (log-rank P=0.12; Figure III in the Data Supplement). The incidence of both cardiovascular death and acute MI was numerically lower in group 1, although the difference was not statistically significant. Importantly, all the end points related to repeat revascularization were consistently lower in group 1, when compared with groups 2 and 3 ( Table IV in the Data Supplement). However, patients in group 3 had the highest event rate for all end points considered, with the exception of total mortality. The adjusted hazard of target lesion revascularization (TLR) at 12 months in group 3, taking revascularized patients as the reference category, was 2.38 (95% CI, 1.05-5.43; P=0.039). The corresponding hazard ratio (HR) for group 1 was 0.98 (95% CI, 0.48-1.99; P=0.945.). The observed differences between groups both in total MACE and in target lesion failure were mainly driven by a large increase in the hazard of revascularization events in group 3 ( Table IV in the Data Supplement) .
For the 201 patients in whom an additional stress test would have been undertaken (based on angiography alone), complete follow-up information was available for all but two, who were See Table II in the Data Supplement file for complete information on baseline patient characteristics. ACS indicates acute coronary syndrome; CABG, coronary artery bypass graft; CAD, coronary artery disease; CVD, symptomatic cardiovascular disease other than CAD; EF, ejection fraction; FFR, fractional flow reserve; NSTEMI, non-ST-segment-elevation myocardial infarction; PCI, percutaneous coronary intervention; and STEMI, ST-segment-elevation myocardial infarction.
*P values are for the comparison between management groups. †Proportions refer to patients with evaluation of nonculprit lesions in the setting of a recent ACS (n=95). ‡Average±SD per-patient. §The remaining patients were referred for CABG. FFR Impact on Decision Making and 1-Year Outcome alive at 1 year. A management decision that did not include additional testing was made based on FFR in all cases ( Figure  3 ). The 1-year MACE rate in this group was 6.5%, which compares favorably to the reminder of the reclassified population (4.6%; P=0.9). In the subgroup of patients in whom all lesions were deferred based on FFR (n=86), 3 events occurred at 12 months (3.5%): 2 were ad hoc revascularizations based on physician's decision (no further evidence of ischemia or angina), and 1 non-ST-segment-elevation ACS with no evidence of disease progression and no subsequent intervention performed.
Per-Lesion Analysis
For the purpose of the per-lesion analysis, all fatal events of unknown cause were adjudicated as cardiovascular deaths and any ischemic events (including death) for which a detailed or unequivocal description was not available were considered possibly related to a study lesion. Results are summarized in Figure 4B ; Table V in the Data Supplement. Taken together, the combined 1-year rate of cardiovascular death or MI definitely or possibly related to a study lesion was significantly lower in group 1 than in groups 2 and 3 (0.7% versus 2.2% versus 2.9%; P=0.047). TLR occurred in 2.7% of the deferred lesions from group 1, a rate that was similar to revascularized lesions (adjusted HR, 1.23; 95% CI, 0.61-2.76; P=0.496). Overall, the main reason reported by investigators for performing TLR was chest pain interpreted as angina (52.6%), either accompanied by a positive noninvasive stress test or invasive evidence of disease progression, or MI. Importantly, in group 1, a significant proportion of events was driven by chest pain with no other evidence of ischemia (21%) or simply by ad hoc operator decision (without associated symptoms or evidence of ischemia; Table  VI in the Data Supplement). Both the composite of death/MI in relation to study lesion or TLR (adjusted HR, 3.1; 95% CI, 1.28-7.54; P=0.012) and isolated TLR (adjusted HR, 4.7; 95% CI, 1.8-12.3; P=0.001) were significantly higher in group 3 than in group 2 lesions ( Figures 4B and 5C and 5D ).
Predictors of TLR in All Deferred Lesions
From the 1285 lesions evaluated at baseline, 794 (61.8%) were deferred by operator decision: 724 (56.4%) had an FFR>0.80 (group 1) and in the remaining 70, FFR measured ≤0.80 (group 3). Complete follow-up information was available for 786 (99.0%) of the lesions deferred in the index procedure, which were finally included in this subgroup analysis; 26 events occurred in this subset, yielding a rate of TLR of 3.1% at 1 year. The independent predictors of TLR were proximal location of the lesion (HR, 5.43; 95% CI, 2.16-13.65; P<0.001), lesion complexity defined as American College of Cardiology/American Heart Association B2/C type (HR, 2.45; 95% CI, 1.08-5.58; P=0.039), and a lower FFR value (HR [per unit increase], 0.003; 95% CI, 0.0-0.55; P=0.029).
Discussion
The present registry is one of the largest prospective studies ever performed to specifically address the impact of FFR on the management strategy and outcome of patients with known or suspected coronary artery disease undergoing coronary angiography. 8, 9 Our main findings were that (1) routinely using FFR during invasive procedures to guide management was associated with a high proportion of change in treatment decisions, concerning both lesions and patients, (2) patients whose lesions were deferred based on an FFR>0.80 had an outcome that was at least as good as those for which revascularization was deemed necessary, and (3) lesions not revascularized despite an FFR≤0.80 are associated with a dire prognosis. In addition, we have shown that FFR was an independent predictor of TLR in deferred lesions, regardless of stenosis severity, lesion complexity, and classic clinical risk factors such as age, diabetes mellitus, and presentation as ACS.
Management Strategy
The adequacy of angiography to guide decisions on the best management of coronary lesions has been questioned. 7, [10] [11] [12] Several studies have highlighted the disagreement between eyeballing and surrogates of functional significance of lesions (such as FFR) in several subsets of patients, 12 and the use of FFR has been shown to refine risk stratification and patient allocation to available treatment strategies, therefore optimizing clinical outcomes. [13] [14] [15] Accordingly, our data have shown that a change in management strategy occurred in a large proportion of patients (44.2%) and lesions (45.2%) as a direct consequence of FFR evaluation, without reducing the overall number of patients undergoing revascularization (namely by PCI). Three other studies reported on management strategy change based on FFR. In the RIPCORD (Does Routine Pressure Wire Assessment Influence Management Strategy at Coronary Angiography for Diagnosis of Chest Pain?) study 8 
and in the FAMOUS NSTEMI (Fractional Flow Reserve Versus
Angiographically Guided Management to Optimise Outcomes in Unstable Coronary Syndromes) trial, 16 the extent of change was 26% and 21%, respectively, far below the one we found. However, in both studies, all lesions ≥30% had to be interrogated and a significant proportion were either <50% or >70%; truly intermediate lesions (50% to 70%), for which a treatment strategy change was more likely to occur, were less frequent, potentially rendering the impact of FFR less pronounced. However, strategy change in our cohort was similar to the 43% recently reported by Van Belle et al 9 in a large multicenter prospective registry of 1075 patients whose design was closer to POST-IT in that only those lesions in which operators had doubts were included. However, there is a relevant difference in our study because additional imaging stress tests were allowed as a strategy before FFR was performed. Importantly, a final treatment decision was made during the index procedure in all the 22% of patients who would have undergone further stress testing. Not only these patients had a favorable outcome, particularly when all lesions were deferred based on FFR, but also a potential reduction in downstream costs, due to the avoidance of additional testing, new procedures and hospitalizations. Importantly, as opposed to common belief, the use of FFR did not reduce the proportion of patients undergoing revascularization, either by PCI or CABG, even when those initially allocated to subsequent stress tests were not considered in the analysis.
Patient and Lesion Study Groups
Considering the study design, with broad acceptance and few exclusion criteria, a significant heterogeneity in the final patient sample was to be expected, thus making it necessarily difficult to obtain homogenous groups for evaluating the outcome only as a function of FFR-derived management. The rationale underlying our approach was to define study groups in a way that they would resemble relevant populations in randomized trials as much as possible. As such, the deferred arm of the DEFER 17 trial and the registry group of the FAME-2 4 trial (lesions with FFR above the ischemic threshold) are represented in group 1 (comprising patients in whom all study lesions were deferred, despite the fact other lesions could be present but were not evaluated or treated), and the medical therapy arm of the FAME-2 trial 4 is represented by group 3 patients (in whom at least 1 lesion with an FFR≤0.80 was left untreated). One could argue that this division is arbitrary and that there were relevant disparities between groups that could justify differences on clinical outcome on their own, which in fact could be true. To adjust for these differences, adjusted HRs were calculated including relevant variables in the regression models. In addition, in the per-lesion analyses, not only were the study groups completely homogeneous about the management of study lesions based on FFR values but also the outcome measures mirrored those from the per-patient analyses.
Outcome of Deferred Lesions With FFR>0.80
Our results clearly indicate that deferring lesions with an FFR value above the established cutoff of 0.80 is associated with a low event rate at 1 year. The crude incidence of all predefined end points was the lowest in this group, both per-patient and per-lesion, with the exception of TLR in the per-lesion analysis. However, when only those revascularization events for which there was a clear indication were considered (excluding, for instance, ad hoc PCI of a study lesion in the absence of ischemia, ACS or angina), the TLR rate was actually lower than in groups 2 and 3. The incidence of cardiac death and TLR were comparable to the annualized incidence of the same end points reported in the deferral arm of the DEFER trial, 17 and the rates of new unplanned revascularization and MI were roughly the same as those in the registry arm of the FAME-2 trial. 4 Importantly, the absolute incidence of hard clinical end points not related to revascularization (cardiac death or acute MI) that could be definitely or possibly attributed to a study lesion was <1%. Overall, when differences in baseline characteristics were taken into account, the cumulative hazard of MACE for both lesions and patients not revascularized based on an FFR>0.80 was similar to the hazard of those deemed to need PCI or CABG.
Outcomes of Deferred Lesions With an FFR≤0.80
A small subgroup of lesions (n=70) and patients (n=66) were not revascularized because of operators' decision, despite functional evaluation revealing an FFR≤0.80. The reasons for deferring these lesions were not clear. The fact that patients in this group presented less often with severe symptoms and had a higher prevalence of multivessel and complex disease may have been a justification for operators to avoid revascularization.
In the per-patient analysis, MACE rate was higher in this group, a difference that was essentially driven by the need for new unplanned revascularization, as the incidence of cardiovascular death or MI did not differ significantly. The main reasons reported by investigators for unplanned revascularization procedures in this group were mostly related to documented ischemia, MI (that could not be attributed to other lesions), and disease progression (Table VI in the Data Supplement). The FAME-2 investigators have reported similar findings, and in fact, urgent revascularization drove the study primary end point in favor of the upfront PCI strategy in lesions with an FFR≤0.80. 4 Notably, event rates in group 3 were similar to those reported in medical therapy patients of the FAME-2 trial (total death: 1.5% versus 0.7%, MI: 3.0% versus 3.2%; and any revascularization: 19.7% versus 19.5%, respectively).
The best interaction between the primary end point of death/MI or urgent revascularization and FFR in deferred lesions in FAME-2 was 0.65, far below the mean 0.75±0.07 of group 3 lesions in our cohort. However (as shown in Figure IV in the Data Supplement), there is a clear association between the FFR value and the adjusted hazard of hard clinical events at 1 year, because the risk sharply increased below 0.70.
It cannot be excluded that the high rate of unplanned revascularization in group 3 could be a reflection of the nonblinded nature of treatment, possibly rendering treating physicians prone to interpret symptoms as being ischemia related and to perform revascularization. In the 70 lesions with an FFR≤0.80 that were left untreated, the crude incidence of death from cardiovascular cause or MI that could be definitely or possibly related to a study lesion was the highest among the 3 groups (2.9%), as opposed to lesions in group 1, which had the lowest event rate (0.7%).
The link between coronary flow impairment due to any given fixed stenosis and the risk of plaque instability leading to clinically meaningful acute thrombotic events is a matter of debate. 18 Despite the evidence that local flow conditions in the neighborhood of more complex and stenotic lesions may facilitate plaque erosion and that plaque morphological features known to be associated with future ACS are more frequently associated with surrogates of inducible ischemia, 19, 20 trials performed in the setting of stable coronary artery disease have failed to demonstrate that revascularization significantly reduces the risk of hard clinical events, such as cardiac death or acute MI. 4, [21] [22] [23] However, in many of these trials the ischemic burden was unknown or was only mild. 21, 24 In a recently published meta-analysis of 3 randomized trials (SWISSI [Swiss Interventional Study on Silent Ischemia], FAME-2, and the nuclear substudy of the COURAGE [Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation] trial) of medical therapy versus PCI including 1557 patients with documented ischemia or an FFR≤0.80, PCI was associated with a significant 48% mortality reduction (95% CI, 0.30-0.92; P=0.02) at 3 years of follow-up. 25 
Strengths and Limitations
Considering that barely any exclusion criteria existed and that there were no specific recommendations as to which patients to include or how to guide treatment according to FFR, our results truly reflect current clinical practice.
The limitations of our registry are related to its observational design. Despite adequate statistical corrections, it cannot be definitely ruled out that differences in clinical outcome are not a consequence of baseline patient profile, rather than the adequacy of treatment based on FFR value. Only a matched analysis of patients and lesions with comparable risk could further clarify these findings; however, the small sample size of group 3 patients and lesions would necessary render it underpowered to allow meaningful conclusions.
Also, the per-lesion analysis of clinical events (namely cardiovascular death and MI) is limited by the fact that there is no way to definitively confirm that any given event is related with a specific lesion. However, by applying a worst-case-scenario approach (meaning that whenever in doubt, events were attributed to the study lesion), event rates would be, at the most, overestimated, but by the same extent in all 3 groups. FFR Impact on Decision Making and 1-Year Outcome As stated above, the fact that FFR value was known may have influenced revascularization decisions in lesions not treated with an FFR≤0.80. Finally, a longer follow-up duration would be needed to further confirm our observations.
Conclusions
The results from our registry show that routine assessment of coronary lesions using FFR changes management strategy in a high proportion of cases. Also, they are largely confirmatory of seminal randomized trials and highlight the applicability of FFR to guide treatment of real-world patients with broad indications for coronary angiography. FFR accurately identified patients (and lesions) with a low likelihood of events, in which revascularization could be safely deferred, as opposed to those at high risk when ischemic lesions are left untreated.
